Valvular heart disease in hyperprolactinemic patients treated with low doses of cabergoline.
نویسندگان
چکیده
Bohun CM, Potts JE, Casey BM, Sandor GG. A population-based study of cardiac malformations and outcomes associated with dextrocardia. Am J Cardiol. 2007;100:305–9. Icardo JM, Garcia Rincon JM, Ros MA. Malformaciones cardı́acas, heterotaxia y lateralidad. Rev Esp Cardiol. 2002;55:962–74. Perloff JK. The cardiac malpositions. Am J Cardiol. 2011;108:1352–61. Palacios IF. Sustitución percutánea de válvula aórtica. Un enfoque multidisciplinario, la clave del éxito. Rev Esp Cardiol. 2012;65 Supl 2:29–32. López-Otero D, Teles R, Gómez-Hospital JA, Balestrini CS, Romaguera R, SaaibiSolano JF, et al. Implante percutáneo de válvula aórtica: seguridad y eficacia del tratamiento del homoinjerto aórtico disfuncionante. Rev Esp Cardiol. 2012;65: 350–5.
منابع مشابه
Valvular Heart Disease in Patients with Prolactinomas on Cabergoline Treatment
Dopamine agonists are the first line treatment of prolactinomas and Parkinson’s disease. Has shown an association between the use of high doses of ergot dopamine agonists, cabergoline and pergolide, and development of clinically significant (moderate to severe) heart valve regurgitation, valvular thickening and retraction in patients with Parkinson’s disease [1,2]. Because of this, he has appea...
متن کاملA Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline.
CONTEXT Uncertainty exists whether the long-term use of ergot-derived dopamine agonist (DA) drugs for the treatment of hyperprolactinemia may be associated with clinically significant valvular heart disease and whether current regulatory authority guidelines for echocardiographic screening are clinically appropriate. OBJECTIVE Our objective was to provide follow-up echocardiographic data on a...
متن کاملCabergoline and the risk of valvular lesions in endocrine disease.
AIMS The cardiac valvular risk associated with lower exposure to cabergoline in common endocrine conditions such as hyperprolactinemia is unknown. METHODS AND RESULTS We performed a cross-sectional, case-control echocardiographic study to assess the valvular status in 102 subjects receiving cabergoline for endocrine disorders and 51 matched control subjects. Cabergoline treatment ranged from ...
متن کاملComparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
OBJECTIVE It is well known that bromocriptine has a suppressive effect on the prolactin release in hyperprolactinemic patients. But it also has some adverse effects. The new, long-acting dopaminergic drug, cabergoline, has been reported to be an effective agent in these patients. However, there are relatively few reports comparing the beneficial and adverse effects of these drugs in the treatme...
متن کاملA comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.
BACKGROUND Cabergoline is a long-acting dopamine-agonist drug that suppresses prolactin secretion and restores gonadal function in women with hyperprolactinemic amenorrhea. We designed a study to compare its safety and efficacy with those of bromocriptine, which has been the standard therapy. METHODS A total of 459 women with hyperprolactinemic amenorrhea were treated with either cabergoline ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Revista espanola de cardiologia
دوره 66 5 شماره
صفحات -
تاریخ انتشار 2013